000287258 001__ 287258
000287258 005__ 20241030150643.0
000287258 0247_ $$2doi$$a10.3390/ph17010076
000287258 0247_ $$2pmid$$apmid:38256909
000287258 037__ $$aDKFZ-2024-00190
000287258 041__ $$aEnglish
000287258 082__ $$a610
000287258 1001_ $$aMiederer, Matthias$$b0
000287258 245__ $$aAlpha-Emitting Radionuclides: Current Status and Future Perspectives.
000287258 260__ $$aBasel$$bMDPI$$c2024
000287258 3367_ $$2DRIVER$$aarticle
000287258 3367_ $$2DataCite$$aOutput Types/Journal article
000287258 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1706019574_7566$$xReview Article
000287258 3367_ $$2BibTeX$$aARTICLE
000287258 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000287258 3367_ $$00$$2EndNote$$aJournal Article
000287258 520__ $$aThe use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.
000287258 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000287258 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000287258 650_7 $$2Other$$aactinium-225
000287258 650_7 $$2Other$$aalpha emitter
000287258 650_7 $$2Other$$ahigh let
000287258 650_7 $$2Other$$atargeted alpha therapy
000287258 650_7 $$2Other$$atheranostic
000287258 7001_ $$0P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aBenešová-Schäfer, Martina$$b1$$udkfz
000287258 7001_ $$00000-0003-1906-3186$$aMamat, Constantin$$b2
000287258 7001_ $$aKästner, David$$b3
000287258 7001_ $$00000-0002-6432-5694$$aPretze, Marc$$b4
000287258 7001_ $$aMichler, Enrico$$b5
000287258 7001_ $$aBrogsitter, Claudia$$b6
000287258 7001_ $$aKotzerke, Jörg$$b7
000287258 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b8
000287258 7001_ $$aScheinberg, David A$$b9
000287258 7001_ $$aMcDevitt, Michael R$$b10
000287258 773__ $$0PERI:(DE-600)2193542-7$$a10.3390/ph17010076$$gVol. 17, no. 1, p. 76 -$$n1$$p76$$tPharmaceuticals$$v17$$x1424-8247$$y2024
000287258 8564_ $$uhttps://inrepo02.dkfz.de/record/287258/files/pharmaceuticals-17-00076.pdf
000287258 8564_ $$uhttps://inrepo02.dkfz.de/record/287258/files/pharmaceuticals-17-00076.pdf?subformat=pdfa$$xpdfa
000287258 909CO $$ooai:inrepo02.dkfz.de:287258$$pVDB
000287258 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000287258 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000287258 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000287258 9141_ $$y2024
000287258 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICALS-BASE : 2022$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:01:23Z
000287258 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:01:23Z
000287258 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:01:23Z
000287258 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:01:23Z
000287258 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000287258 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000287258 9201_ $$0I:(DE-He78)E270-20160331$$kE270$$lNWG Molekularbiologie Systemischer Radiotherapie$$x0
000287258 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK Koordinierungsstelle Dresden$$x1
000287258 980__ $$ajournal
000287258 980__ $$aVDB
000287258 980__ $$aI:(DE-He78)E270-20160331
000287258 980__ $$aI:(DE-He78)DD01-20160331
000287258 980__ $$aUNRESTRICTED